<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04919226</url>
  </required_header>
  <id_info>
    <org_study_id>DP-1111-02CT</org_study_id>
    <nct_id>NCT04919226</nct_id>
  </id_info>
  <brief_title>Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE</brief_title>
  <acronym>COMPOSE</acronym>
  <official_title>A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ITM Solucin GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ITM Solucin GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy, safety &amp; patient-reported outcomes of&#xD;
      peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of&#xD;
      treatment compared to best standard of care in patients with well-differentiated aggressive&#xD;
      grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of&#xD;
      gastroenteric or pancreatic origin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Every 12 weeks from randomization until disease progression or death whichever occurs earlier, during the time necessary to observe 148 Progression Free Survival (PFS) events.</time_frame>
    <description>PFS (Progression-Free Survival), defined as the time from randomization until documented RECIST v1.1 (Response evaluation criteria in solid tumors) progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years after disease progression</time_frame>
    <description>OS (Overall Survival), defined as the time from randomization until death;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Peptide Receptor Radionuclide Therapy (PRRT) Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CAPTEM(Capecitabine-Temozolomide), Everolimus, FOLFOX(Folinic acid + Fluorouracil + Oxaliplatin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT</intervention_name>
    <description>Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.</description>
    <arm_group_label>Peptide Receptor Radionuclide Therapy (PRRT) Arm</arm_group_label>
    <other_name>177Lu-DOTATOC 177Lu-Edo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAPTEM (Capecitabine and Temozolomide)</intervention_name>
    <description>Best standard of care treatment (investigator's choice [from the protocol comparator list]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.</description>
    <arm_group_label>CAPTEM(Capecitabine-Temozolomide), Everolimus, FOLFOX(Folinic acid + Fluorouracil + Oxaliplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Amino-Acid Solution</intervention_name>
    <description>The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.</description>
    <arm_group_label>Peptide Receptor Radionuclide Therapy (PRRT) Arm</arm_group_label>
    <other_name>Arginine-Lysine Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus 10 mg</intervention_name>
    <description>Best standard of care treatment (investigator's choice [from the protocol comparator list]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.</description>
    <arm_group_label>CAPTEM(Capecitabine-Temozolomide), Everolimus, FOLFOX(Folinic acid + Fluorouracil + Oxaliplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)</intervention_name>
    <description>Best standard of care treatment (investigator's choice [from the protocol comparator list]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.</description>
    <arm_group_label>CAPTEM(Capecitabine-Temozolomide), Everolimus, FOLFOX(Folinic acid + Fluorouracil + Oxaliplatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged â‰¥ 18 years.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of unresectable, well-differentiated&#xD;
             GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs). measurable site of disease&#xD;
             per RECIST v1.1 (Response evaluation criteria in solid tumors) using contrast computed&#xD;
             tomography (CT) / magnetic resonance imaging (MRI).&#xD;
&#xD;
          -  Somatostatin receptor-positive (SSTR+) disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to Lutetium 177Lu, edotreotide, DOTA (dodecane tetraacetic&#xD;
             acid), any of the comparators, or any excipient or derivative (e.g. rapamycin).&#xD;
&#xD;
          -  Prior (Peptide Receptor Radionuclide Therapy) PRRT.&#xD;
&#xD;
          -  Any major surgery within 4 weeks prior to randomization in the trial.&#xD;
&#xD;
          -  Therapy with an investigational compound and/or medical device within 30 days or 7&#xD;
             half-life periods (whichever is longer) prior to randomization.&#xD;
&#xD;
          -  Other known malignancies.&#xD;
&#xD;
          -  Serious non-malignant disease.&#xD;
&#xD;
          -  Renal, hepatic, cardiovascular, or hematological organ dysfunction, potentially&#xD;
             interfering with the safety of the trial treatments.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Patients not able to declare meaningful informed consent on their own or any other&#xD;
             vulnerable population to that.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas Schneider, Dr</last_name>
    <email>info@itm-solucin.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martina Herrmann, MD</last_name>
    <email>info@itm-solucin.de</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GastroEnteroPancreatic</keyword>
  <keyword>non-functional and functional GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NET)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Edotreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

